| Literature DB >> 31615650 |
Dimitrios Farmakis1, Piergiuseppe Agostoni2, Loant Baholli3, Andrei Bautin4, Josep Comin-Colet5, Maria G Crespo-Leiro6, Francesco Fedele7, Jose Manuel García-Pinilla8, George Giannakoulas9, Francesco Grigioni10, Marcin Gruchała11, Finn Gustafsson12, Veli-Pekka Harjola13, Tal Hasin14, Antoine Herpain15, Efstathios K Iliodromitis16, Kristjan Karason17, Matti Kivikko18, Lucas Liaudet19, Jana Ljubas-Maček20, Marco Marini21, Josep Masip22, Alexandre Mebazaa23, Maria Nikolaou24, Petr Ostadal25, Pentti Põder26, Piero Pollesello27, Eftihia Polyzogopoulou28, Gerhard Pölzl29, Carsten Tschope30, Marjut Varpula31, Dirk von Lewinski32, Bojan Vrtovec33, Mehmet Birhan Yilmaz34, Endre Zima35, John Parissis36.
Abstract
Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure.Entities:
Keywords: Acute heart failure; Advanced heart failure; Dobutamine; Inodilators; Inotropes; Levosimendan; Milrinone; Norepinephrine
Mesh：
Substances：
Year: 2019 PMID： 31615650 DOI： 10.1016/j.ijcard.2019.09.005
Source DB: PubMed Journal: Int J Cardiol ISSN： 0167-5273 Impact factor: 4.164